NattoPharma

NattoPharma (OSL:NATTO) (Lysaker, Norway 17 November 2008) The European Food Safety Authority (EFSA) has published a positive scientific opinion on vitamin K2, MK-7 from natto as a dietary supplement and food ingredient. The positive EFSA-opinion gives NattoPharma ASA a solid platform for wide distribution of MenaQ7(TM) in Europe.

NattoPharma (OSL:NATTO) 13 November 2008, Lysaker, Norway -NattoPharma and PL Thomas, announced significant exposure and discussion of Vitamin K2 and its role in promoting cardiovascular health at the American Society of Nephrology's Renal Week 2008 in Philadelphia. Of note, four key presentations, including two abstracts, a poster and a feature presentation by Leon Schurgers, PhD, Senior Scientist at the Cardiovascular Research Institute Maastricht (CARIM) at the University of Maastricht, all discussed the significance of adequate vitamin K2 intake for the prevention of vascular calcification in both healthy and diseased populations. The source of natural vitamin K2 used in the studies was MenaQ7, natural vitamin K2.

NattoPharma (OSL:NATTO) 14.10.2008, Lysaker, Norway - NattoPharma would like to notify a new publication by Avgeri et al. (J Pediatr Hematol Oncol), about the association of long-term oral anticoagulant therapy (OAC) resulting in a remarkable reduction in bone mineral density and significant impairment in other bone health parameters.

NattoPharma (OSL:NATTO) NattoPharma ASA has acquired all shares of MGP Diagnostics AS, securing ownership of a granted patent that is the key to the development of a new diagnostic test concept. This concept may determine the need for the natural vitamin K2 product Mena Q7(TM), to which NattoPharma has exclusive rights.

NattoPharma (OSL:NATTO) (Lysaker, Norway, 11 September 2008) NattoPharma ASA has entered into an exclusive distribution agreement with Pathway International Pty Ltd for the natural K2 vitamin product MenaQ7(TM) in Australia and New Zealand. The agreement is an important element in NattoPharma's strategy to ensure global distribution of MenaQ7(TM).

NattoPharma (OSL:NATTO) 10th of September 2008, Lysaker - NattoPharma and PL Thomas are pleased to announce that a new study demonstrated the association of high dietary Vitamin K2 consumption with reduction of coronary calcification in humans. Accepted by the journal Atherosclerosis, this study is now available online. http://www.atherosclerosis-journal.com/article/S0021-9150(08)00507-8/abstract

NattoPharma (OSL:NATTO)

NattoPharma (OSL:NATTO) NattoPharma ASA and PL Thomas proudly announce that NattoPharma's natural vitamin K2 product, MenaQ7(TM), has received the prestigious 2008 Frost & Sullivan Product Innovation of the Year Award in the North American Vitamin market. According to Frost & Sullivan "The award is in recognition of the company's unique capability to develop natural vitamin K2 as MenaQ7(TM) with established and proven bone and heart health benefits. Owing to its natural form coupled with superb bioavailability, MenaQ7 obtained excellent market acceptance."

NattoPharma (OSL:NATTO) On behalf of NattoPharma, Orion Securities would like to invite shareholders, investors and other interested parties to a lunch presentation in connection with the release of NattoPharma ASA's second quarter results 2008.

NattoPharma 16 July 2008, Lysaker, Norway - NattoPharma and PL Thomas announce today a new study has published in the journal Clinical and Experimental Rheumatology 2008; 26(3):484-91) discussing the association between the vitamin K-dependent protein osteocalcin and the incidence of low bone mass in children with juvenile idiopathic arthritis.